332 Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31:2296–2303 Ramaekers JG, Kuypers KP (2006) Acute effects of 3, 4- methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol. Neuro- psychopharmacology 31:1048–1055 Ramaekers JG, Muntjewerff ND, Van Veggel LMA, Uiterwijk MMC, O'Hanlon JF (1998) Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance of healthy volunteers. Hum Psychopharmacol 13: S87–S97 Ramaekers JG, Swijgman HF, O'Hanlon JF (1992) Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology (Berl) 106 Suppl:S62–S67 Ridout F, Meadows R, Johnsen S, Hindmarch I (2003) A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 18:261–269 Ruigt GS, Kemp B, Groenhout CM, Kamphuisen HA (1990) Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 38:551–554 Schmid DA, Wichniak A, Uhr M, Ising M, Brunner H, Held K, Weikel JC, Sonntag A, Steiger A (2006) Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, Psychopharmacology (2011) 215:321–332 and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 31:832– 844 Stahl SM (2008) Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 13:1027–1038 Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4–15 van Laar M, Volkerts E, Verbaten M (2001) Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2 C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 154:189–197 Vermeeren A (2004) Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18:297–328 Wingen M, Bothmer J, Langer S, Ramaekers JG (2005) Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66:436–443 Wingen M, Langer S, Ramaekers JG (2006) Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant. Hum Psycho- pharmacol 21:473–479 Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA (2000) Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 48:75–78